Ask what drives aging and you will get a list: cells wear out, DNA accumulates errors, mitochondria falter, tissues stiffen. All true. But run through the major diseases of later life — heart attack, stroke, type 2 diabetes, Alzheimer's, many cancers, the slide into frailty — and a single, quieter factor keeps surfacing beneath all of them. Not a dramatic fire, but a slow one: chronic, low-grade inflammation that never quite switches off. Scientists gave this phenomenon a deliberately ugly, memorable name — inflammaging — and it has become one of the most productive ideas in the biology of aging.
Inflammation is supposed to be your friend
To grasp why chronic inflammation is so damaging, start with why acute inflammation is so good. When you cut your finger or catch a virus, your immune system floods the area with inflammatory signals: blood vessels dilate, immune cells swarm in, and the invader or damage is dealt with. Redness, heat and swelling are the visible signs of a system working exactly as designed. Crucially, healthy inflammation is self-limiting — once the threat is cleared, an active resolution programme shuts it down and returns the tissue to calm. Intermittent bursts of inflammation are not just survivable; they are essential for survival.
Inflammaging is what happens when that beautifully controlled process loses its off-switch. Instead of sharp, resolving spikes, the body settles into a persistent, smouldering activation — low in intensity, but never resolving, running quietly in the background for years. It is inflammation without a wound, defence without an enemy. And because it is low-grade, it produces no fever, no swelling, nothing you can feel. You cannot sense inflammaging; you can only measure it, in the form of chronically elevated inflammatory markers in the blood.
What "systemic chronic inflammation" actually is
In a widely cited 2019 perspective in Nature Medicine, an international group led by Furman and Franceschi laid out the modern framework, using the term systemic chronic inflammation (SCI). Unlike the acute kind, they wrote, SCI is a persistent, low-grade activation of the immune system that can, over time, cause collateral damage across multiple organs — and they directly linked it to the diseases that represent the leading causes of disability and death worldwide, including cardiovascular disease, cancer, diabetes, chronic kidney disease, non-alcoholic fatty liver disease, and autoimmune and neurodegenerative disorders.[1]
What keeps the fire lit? Several sources feed it, and they accumulate with age. Worn-out “senescent” cells, which resist dying, secrete a cocktail of inflammatory signals (the so-called senescence-associated secretory phenotype). Visceral fat — the metabolically active fat around the organs — behaves like an inflammatory gland. The gut becomes slightly leakier with age, letting bacterial fragments trickle into circulation. Damaged mitochondria spill molecules that the immune system reads as danger. Layered on top are the modern amplifiers the Furman group emphasised: physical inactivity, poor diet, disturbed sleep, chronic psychological stress, and environmental exposures.[1] Inflammaging, in other words, is not one thing with one cause; it is a convergence.
The through-line of age-related disease
The reason inflammaging commands so much attention is its breadth. Franceschi and Campisi, in an influential review, framed chronic inflammation as a potential common driver linking the major age-associated diseases rather than a coincidental bystander of each one separately.[2] That is a powerful reframing: instead of heart disease, diabetes and dementia being unrelated misfortunes that happen to cluster in old age, inflammaging suggests they may partly share a root.
The mechanistic logic is consistent across organs. In arteries, inflammatory cells drive the formation and rupture of atherosclerotic plaques. In metabolism, inflammatory signalling interferes with insulin's action, nudging toward type 2 diabetes. In the brain, chronic neuroinflammation is increasingly implicated in neurodegeneration. In muscle and across the body, inflammation promotes catabolism — the breakdown of tissue — feeding the slide into sarcopenia and frailty. Ferrucci and Fabbri, in a 2018 review in Nature Reviews Cardiology, catalogued exactly this: inflammaging as a risk factor not only for cardiovascular disease but for chronic kidney disease, diabetes, cancer, depression, dementia and sarcopenia — and, importantly, noted that clinical-trial evidence suggests the link to cardiovascular disease is causal.[3]
Marker or cause? The trial that mattered
Here is the question that separates a neat theory from an actionable one. Chronic inflammation is reliably associated with all these diseases — but association is not causation. Sick and aging bodies inflame; perhaps inflammation is simply a readout of underlying damage rather than a cause of it. To break that deadlock you need to lower inflammation specifically, change nothing else, and see whether outcomes improve.
That is precisely what the CANTOS trial did, and it is why it was a landmark. Ridker and colleagues, reporting in the New England Journal of Medicine in 2017, randomized more than 10,000 people who had survived a heart attack and had elevated inflammation (high-sensitivity CRP of 2 mg/L or more) to either canakinumab — a monoclonal antibody that blocks the inflammatory signal interleukin-1β — or placebo.[4] The elegance was in what canakinumab does not do: it has no effect on cholesterol. So any benefit could be attributed to reducing inflammation alone. At the 150 mg dose, canakinumab significantly lowered the rate of recurrent major cardiovascular events by roughly 15% compared with placebo, with no change in lipid levels.[4]
For the first time, this showed that targeting inflammation itself — not cholesterol, not blood pressure — reduces cardiovascular risk in humans. It moved inflammaging from “interesting marker” toward “treatable cause,” at least for the heart. The honest boundaries matter, though: canakinumab also modestly raised the risk of fatal infection, did not lower overall mortality, and is expensive, so it was never going to become a routine anti-aging drug. Its value was as a proof of principle. The causal arrow, for cardiovascular disease, points at least partly from inflammation to disease.
Why you can't extrapolate too far
It would be easy to over-read CANTOS as license to declare inflammation the master cause of aging and to start “treating” it broadly. Resist that. The trial proved causality for one disease, in one high-risk population, using one specific drug against one inflammatory pathway. It did not show that suppressing inflammation prevents dementia, or cancer, or extends lifespan — and blunting the immune system carries real costs, as the infection signal in CANTOS demonstrated. Inflammation exists because we need it.
This is the mature version of the inflammaging story, and it is more useful than the hype. Chronic inflammation is a genuine, measurable, mechanistically plausible thread through age-related disease; it is proven causal for cardiovascular disease and strongly implicated elsewhere; and it is emphatically not something to carpet-bomb with immunosuppressants in healthy people. The goal is not to abolish inflammation but to restore its balance — to stop feeding the chronic fire while preserving the acute response that keeps you alive.
What actually cools the fire
The most encouraging part of the inflammaging framework is how modifiable it is by the least exotic means. The interventions that lower chronic inflammatory markers are, almost without exception, the same foundations that define healthy aging — which is either a remarkable coincidence or a strong hint that inflammation is part of why those foundations work.
- Move regularly. Physical activity has a well-documented anti-inflammatory effect over time, and contracting muscle itself releases signals that counter inflammation. Inactivity, conversely, is a listed driver of chronic inflammation.
- Lose excess visceral fat. Abdominal fat is an active source of inflammatory signalling, so reducing it directly turns down one of the loudest sources of the smoulder.
- Prioritise sleep. Short and disrupted sleep raises inflammatory markers; consistent, sufficient sleep lowers them.
- Eat mostly whole plants. A diet high in fibre, vegetables, fruit, legumes and unsaturated fats is associated with lower inflammation; one dominated by ultra-processed food and refined sugar with higher inflammation. Whole foods beat any “anti-inflammatory” supplement.
- Don't smoke, and manage stress. Smoking is powerfully pro-inflammatory, and chronic psychological stress keeps inflammatory pathways switched on — both are explicitly named drivers of systemic chronic inflammation.[1]
Notice that none of this requires a novel drug or a costly supplement. The same short list of habits that protects your heart, your metabolism and your muscle appears to work partly by keeping the slow fire of inflammaging low. That convergence is the practical payoff of the whole idea.
The honest bottom line
Inflammaging is one of the most compelling organising ideas in longevity science: a single, measurable process that plausibly connects the diseases we most fear in later life, with genuine trial evidence that it drives at least cardiovascular disease. It reframes aging not as inevitable decay but partly as an inflammatory imbalance — and imbalances can be nudged.
But it is a lens, not a magic bullet. The evidence is strongest for the heart and still maturing elsewhere, immune suppression is a blunt and risky tool, and there is no pill that safely “cures” inflammaging today. What there is, reassuringly, is a set of ordinary levers — movement, healthy body composition, sleep, food, not smoking — that measurably lower chronic inflammation and happen to be the best-evidenced longevity habits we have. The slow fire is real. The most reliable way to keep it low is also the most familiar.